← Search & browse all drugs
SENSORY ORGANS › OPHTHALMOLOGICALS › DECONGESTANTS AND ANTIALLERGICS › Other antiallergics
azelastine
S01GX07
Forms & Strengths
- Nasal spray 0.1% solution (0.5 mg per spray)
- Ophthalmic solution 0.05% (0.5 mg/mL)
Adult Dosing
- Allergic rhinitis: 1 spray/nostril twice daily (≈1 mg total)
- Allergic conjunctivitis: 1‑2 drops/eye twice daily
Pediatric Dosing
- Nasal spray (≥12 yr): same as adult
- Nasal spray (6‑11 yr): 1 spray/nostril twice daily (≈0.5 mg per dose)
- Ophthalmic drops (≥3 yr): 1 drop/eye twice daily
- Not recommended for children <3 yr (ocular) or <6 yr (nasal)
Indications
- Seasonal and perennial allergic rhinitis
- Allergic conjunctivitis (vernal, seasonal)
Mechanism of Action
- Selective peripheral H1‑receptor antagonist
- Mast‑cell stabilizer reducing histamine release
- Inhibits eosinophil chemotaxis and cytokine production
Contraindications
- Hypersensitivity to azelastine or excipients
Adverse Reactions
- Nasal burning, stinging, itching
- Bitter taste, dysgeusia
- Drowsiness, fatigue, headache
- Epistaxis, nasal dryness
- Ocular burning, itching, conjunctival hyperemia
- Transient blurred vision
Drug Interactions
- Additive sedation with alcohol, CNS depressants, other antihistamines
- CYP3A4 inhibitors (ketoconazole, erythromycin) may increase systemic exposure
- CYP3A4 inducers (rifampin, carbamazepine) may reduce effect
- Concurrent anticholinergics may enhance dryness
Curated Content: Needs Vetting Before Put to Clinical Use